Phase II trials in Ta, Tl bladder cancer. the marker tumour concept

British Journal of Urology

Volumn 77, Issue 5, 1996, Pages 634-637

  Van Der Meijden, A P M ^{a,b,c,d,e,f,g}   Hall, R R ^a   Kurth, K H ^a,b   Bouffioux, Ch ^a,b,c   Sylvester, R ^a,b,c,d  

^a EORTC Genitourinary Group   (Netherlands)

^b European Organisation of Research and Treatment on Cancer (Genitourinary Group)   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d FREEMAN HOSPITAL   (United Kingdom)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g EORTC DATA CENTER   (Belgium)

Author keywords

Marker lesion; Phase ii trials; T1 bladder cancer; Ta

Indexed keywords

BCG VACCINE; EPIRUBICIN; MITOMYCIN C; TUMOR MARKER;

BLADDER CANCER; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; ENDOSCOPIC SURGERY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSITIONAL CELL CARCINOMA;

CLINICAL TRIALS, PHASE II; HUMANS; PATIENT SELECTION; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 0030417918     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Kurth KH. Denis L, Kate ten FJW et al. Prognostic factors in superficial bladder tumours. Problems in Urology 1992: 6: 471-83
2. Van der Meijden APM, Hall RR. Pavone Macaluso M. Pawinsky A, Sylvester R, Van Glabbeke M. Marker tumour response to the sequential combination of intravesical therapy with Mitomycin C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer Genitourinary Group (EORTC 50897). Eur Ural 1996: 29: 199-2(13
3. Koontz WW. Prout GR. Smith W, Frable WJ. Minnis JE. The use of intravesical Thiotepa in the management of non-invasive carcinoma of the bladder. J Urol 1981: 125: 307-12
4. Parmar M. Freedman L. Hargreave T. Prognostic factors for recurrence and follow up policies in the treatment of superlicial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (urological cancer working party)./ Urol 1989: 142: 284-8
5. EORTC Protocol 30864 and 30869 (see introduction).
6. Soloway MS. Diagnosis and management of superficial bladder cancer. Semin Surg Oncol 1989: 5: 247-54
7. Oosterlinck W. Kurth KH. Schröder F et al. A prospective European Organization for Research and Treatment of Cancer Genito Urinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of Kpirubicin or water in single stage Ta. Tl papillary carcinoma of the bladder. J L'rol 1995: 149: 749-52
8. Bono A. Hall R. Sylvester R cl ni. Topical chemotherapy in superlicial bladder cancer: a chcmoreseetion Phase II study using a marker tumour. Société Internationale d'Urologie. 22nd Congress, Seville. Spain 1991 (Abstract).
9. Hall RR. Transurethral resection for transitional cell carcinoma. Problems in Urology 1992: 6: 460-70
10. Larnm DL. Meijden van der APM. Akaza H et al. Intravesical chemo- and iinmunotherapy: How do we assess their effectiveness and what are their limitations and uses. Proceedings of the Fourth International Bladder Cancer Consensus Conference, Int J Urol 1995: 2 (suppl. 2): 23-55
11. Fellows G, Parmar .VI. Clrigor R et al. Marker tumour response to Kvans and Pasteur Bacille Calmette-C.uérin in multiple recurrent pTa. p'l'l bladder tumours: Report from the Medical Research Council Subgroup on Superlicial Bladder Cancer (Urologieal Cancer Working Party). Kr J Urol 1994: 75: 639-44
12. Popert RJM. Goodall J, Coptcoat MJ. Superlicial bladder cancer: the rcsponce of a marker tumour to a single intravesical instillation ol Hpirubicin. H r J Urol 1994; 74: I95-6
13. Mcijden van der APM, Kurlli KH, Cheuvart B. Sylvester R. Dehruyne FM. Intravesical ehemotherapy lor superficial bladder cancer. The EORTC Genito Urinary Group experience. In Murphy G, Khoury S, Chatelain C, Denis L. (eds), Recent Advances in Urologic Cancers. Diagnosis and Treatment. 1990: 138-145
14. Hall RR, Parmar H, Richards A, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. Br Med J 1994: 308: 257-60